In accordance with the resolution passed at the extraordinary general meeting on 30 September 2011, NorDiag ASA (the "Company") has now completed a reduction of its share capital by NOK 67,231,082.10. The reduction has been carried out by reducing the nominal value of the shares from NOK 1 to NOK 0.02.
 
Following the reduction, the new share capital of the Company is NOK 1,372,062.90, divided on 68,603,145 shares, each with a nominal value of NOK 0.02.
 
For further information, please contact:
CEO Mårten Wigstøl,  Phone: +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576
 
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
Read the notice in Norwegian here.